Epigenomics' Q2 Revenues Rise Sharply; FDA Decision on Colorectal Cancer Dx Anticipated in H2 | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics today said that revenues in its second quarter increased 120 percent.

The German molecular diagnostic firm reported revenues of €343,000 ($457,000) for the three months ended June 30, up from €157,000 a year ago. Products sales more than doubled to €164,000 from €73,000 in the year-ago period, while licensing income retreated to €59,000 from €83,000.

The firm took in €120,000 in R&D income, compared to none a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.